As it shows in the Intellectual Property Report on Listed Companies in Pharmaceutical Industry of China, a research initiated by Globe-Law Law Firm and co-organized by hexun.com, companies with relatively high business income rank not so high in the overall index indicated in the report. With respect to patent grants, companies within pharmaceutical industry stay unbalanced. "Many companies maintain underperformed in this indicator, 6 of which even have no patent," the report says. Companies thus have to increase input in research and development as well as intellectual property.

Among about 100 A-share listed drug companies, IPR distribution differs variously. When judged by the five ratings based on the scores calculated, only three companies reach a five-star level, senior partner of Globe-Law Law Firm Wang Zhengzhi said.

"It proves sound capacity of research and development will help companies increase their values," said vice president of Chinese Chemical and Pharmaceutical Industry Association Pan Guangcheng.

[Chinese version is available on Securities Daily]

Source:IPR in China